Relapsed

7 registered clinical trials studyying Relapsed — 3 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	A Dose Escalating Study of CD19/CD22/BCMA CAR-T Therapy in Relapsed/ Refractory Multiple Myeloma NCT06732232	Shanghai Cell Therapy Group Co.,Ltd	EARLY_Phase 1
Recruiting	Multicenter, Platform-type Clinical Study of Refractory/Recurrent Acute Myeloid Leukemia NCT06265545	Institute of Hematology & Blood Diseases Hospital, China	N/A
Unknown	Cord Blood Derived CAR-T Cells in Refractory/Relapsed B Cell Malignancies NCT03881774	Henan Cancer Hospital	Phase 1
Unknown	CD19/20 Bispecific Nanobody-derived CAR-T Cells in B Cell Lymphoma NCT03881761	Henan Cancer Hospital	Phase 1
Active Not Recruiting	Combination Therapy With Entinostat and Pembrolizumab in Relapsed and Refractory Lymphomas NCT03179930	Memorial Sloan Kettering Cancer Center	Phase 2
Active Not Recruiting	A Trial of "Armored" CAR T Cells Targeting CD19 For Patients With Relapsed CD19+ Hematologic Malignancies NCT03085173	Memorial Sloan Kettering Cancer Center	Phase 1
Recruiting	Identify Barriers to Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Newly Diagnosed and R NCT02677064	Memorial Sloan Kettering Cancer Center	—